Pfizer Inc. (NYSE:PFE) Shares Purchased by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 1.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 63,673 shares of the biopharmaceutical company’s stock after acquiring an additional 905 shares during the quarter. Pfizer makes up approximately 1.2% of Investors Asset Management of Georgia Inc. GA ADV’s portfolio, making the stock its 18th largest holding. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Pfizer were worth $2,134,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. State Street Corp raised its holdings in shares of Pfizer by 1.9% in the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after buying an additional 5,374,611 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Geode Capital Management LLC grew its holdings in shares of Pfizer by 2.7% during the second quarter. Geode Capital Management LLC now owns 112,872,506 shares of the biopharmaceutical company’s stock worth $4,129,431,000 after purchasing an additional 3,019,727 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the period. Finally, Morgan Stanley raised its position in shares of Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares during the last quarter. 68.05% of the stock is owned by institutional investors.

Pfizer Stock Up 0.4 %

PFE traded up $0.10 during midday trading on Monday, reaching $27.66. 30,270,699 shares of the company were exchanged, compared to its average volume of 44,718,609. The company has a market cap of $156.18 billion, a price-to-earnings ratio of 76.56, a price-to-earnings-growth ratio of 1.22 and a beta of 0.62. The company’s fifty day moving average price is $28.19 and its 200 day moving average price is $31.36. Pfizer Inc. has a one year low of $25.76 and a one year high of $44.20. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38.

Pfizer (NYSE:PFEGet Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the firm posted $1.14 EPS. As a group, analysts expect that Pfizer Inc. will post 2.23 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, January 25th. This is a boost from Pfizer’s previous quarterly dividend of $0.41. This represents a $1.68 annualized dividend and a dividend yield of 6.07%. Pfizer’s payout ratio is 466.67%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PFE shares. Wells Fargo & Company dropped their price target on shares of Pfizer from $39.00 to $35.00 and set an “equal weight” rating for the company in a research note on Monday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, January 31st. BMO Capital Markets cut their target price on Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, October 16th. UBS Group lowered their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Finally, Barclays reduced their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $36.93.

Read Our Latest Research Report on Pfizer

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $26.47 per share, for a total transaction of $79,410.00. Following the completion of the transaction, the director now directly owns 9,000 shares in the company, valued at $238,230. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.